Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
What 30 Years of Clinical Speech Data Teaches Us About AI Accuracy
Atlas Aura, a clinical speech‑recognition platform, leverages three decades of curated medical audio data, giving it a distinct edge over newer, generic AI transcription tools. The deep, domain‑specific dataset enables the system to accurately interpret disordered speech, maintain consistency across diverse patient demographics, and track subtle changes over time. Powered by this foundation, SpeechAmbient extends the technology into real‑time clinical documentation, reducing manual note‑taking. The article argues that in healthcare, reliability and trust stem from data quality, not just rapid feature releases.
DOL’s Overtime Rule Offers At-Home Care Providers Relief, But Does Not Solve Root Problem
The U.S. Department of Labor officially revoked the 2024 overtime rule, restoring the 2019 salary threshold of $35,568 instead of the planned $58,656. Home‑based care providers now face fewer overtime‑eligible staff, easing short‑term payroll and compliance burdens. However, the change...
Astellas Receives CHMP Positive Opinion for Perioperative Padcev + Keytruda for Muscle-Invasive Bladder Cancer (MIBC)
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Astellas’ Padcev (enfortumab vedotin) combined with Keytruda (pembrolizumab) for neoadjuvant and adjuvant treatment of cisplatin‑ineligible patients with resectable muscle‑invasive bladder cancer (MIBC). The...
Re: Calcium, Vitamin D, or Combined Supplementation to Prevent Fractures and Falls: Systematic Review and Meta-Analysis
A rapid response letter published in the BMJ challenges the UK’s longstanding NHS guidance that low‑dose vitamin D (10 µg) combined with calcium prevents fractures. The GP author cites a new systematic review and meta‑analysis that found little evidence of benefit from...
President's Emergency Plan for AIDS Relief (PEPFAR)
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) relies on the FDA to ensure that safe, effective antiretroviral (ARV) medicines are available in low‑resource settings. Since 2004, the FDA’s Center for Drug Evaluation and Research has reviewed ARV marketing...
Tony Robbins and Calm Veterans Raise $14.3M to Launch AI‑Driven Therapy Platform
The Path, a mental‑health startup co‑founded by former Calm data‑science lead Anson Whitmer and engineer Tyler Sheaffer, announced a $14.3 million seed round led by Prime Movers Lab. Backed by Tony Robbins, Olympic gold‑medalist Apolo Anton Ohno, boxer Deontay Wilder and Designer...
Biogen, Denali to Drop Drug in Non-Genetic Parkinson’s After Mid-Stage Study Flop
Biogen and Denali Therapeutics announced that their LRRK2 inhibitor BIIB122 failed to meet primary endpoints in a Phase 2b trial of early‑stage Parkinson’s disease. The mid‑stage study, which targeted patients without the LRRK2 genetic mutation, showed no statistically significant slowing...
Moderna’s Once-Rebuffed mRNA Flu Shot to Face Scrutiny From FDA Adcomm
The FDA will hold its Vaccines and Related Biological Products Advisory Committee on June 18 to evaluate Moderna’s investigational mRNA flu vaccine, MFLUSIVA, aimed at adults 50 and older. Earlier this year the agency issued a refusal‑to‑file letter, arguing the...
Frontline Productivity: A Strategic Imperative for NHS Leaders
Frontline productivity has become a strategic priority for the NHS as it seeks 2% annual efficiency gains outlined in the 2025 Spending Review. The focus is shifting from merely installing technology to embedding electronic patient record (EPR) systems that streamline...
Prior Authorization Delays Vital Transplant Medication
A heart transplant recipient’s experience highlights how prior‑authorization hurdles can jeopardize access to everolimus, a critical immunosuppressive drug. Anthem Blue Cross Blue Shield repeatedly denied coverage, citing the lack of a specific FDA indication for heart transplants, forcing multiple appeals...
As Americans Voice Concerns About Health Care and Lose Trust in Federal Institutions, Here’s How CT Has Responded
Americans are increasingly anxious about health‑care access and affordability, with Gallup reporting 61% worried a great deal—up from 51% two years ago. Trust in federal health agencies such as the CDC, FDA and NIH has slipped by up to 7%...
AI Therapy Platform The Path Secures $14.3M Seed Funding to Scale Mental Health Services
The Path announced a $14.3 million seed round led by Prime Movers Lab, with strategic backing from Tony Robbins, Olympic champion Apolo Anton Ohno, boxer Deontay Wilder and Designer Fund. The capital will fund team growth, mobile rollout and multi‑center clinical research,...
Eli Lilly’s Retatrutide Delivers up to 28% Weight Loss in Phase 3 Trial
Eli Lilly announced that its experimental triple‑agonist retatrutide achieved up to 28.3% weight loss (about 70 lb) over 80 weeks in a pivotal Phase 3 trial, with 45% of participants shedding 30% or more. The data positions the drug as a potential game‑changer...
The Colorectal Cancer Alliance’s Efforts to Improve Screening, Awareness and Outcomes
The Colorectal Cancer Alliance, led by CEO Michael Sapienza, is accelerating research and early detection through its Project Cure CRC initiative, which has funded 33 projects in the past 18 months. The Alliance is launching an adaptive clinical‑trial platform to...
Tempus AI Launches ArteraAI Prostate Test for Metastatic Prostate Cancer
Tempus AI announced the clinical launch of the ArteraAI Prostate Test, a CLIA‑certified and CAP‑accredited prognostic assay for metastatic hormone‑sensitive prostate cancer (mHSPC). The test combines a digital pathology AI algorithm with Tempus’ next‑generation sequencing data to generate personalized risk...
Cyclarity Therapeutics Reports Safety Data for 7-Ketocholesterol Clearance
Cyclarity Therapeutics reported first clinical evidence that its AI‑engineered cyclodextrin drug, UDP‑003, can safely bind and promote urinary excretion of 7‑ketocholesterol, a toxic oxysterol linked to atherosclerosis. The Phase 1 safety trial demonstrated favorable pharmacokinetics and pharmacodynamics, with no serious adverse...
Bristol‑Myers Squibb Seen as Most Undervalued Large‑Cap Healthcare Stock in the S&P 500
Bristol‑Myers Squibb (BMY) is identified as the most undervalued large‑cap healthcare stock in the S&P 500, trading at roughly 10 times forward earnings and 9.9 times trailing free cash flow. The valuation contrasts with a 3 % Q1 revenue rise, a growing newer‑drug...
ACA Marketplace Loses 1.2 Million Enrollees, Premiums Jump 58% as Subsidy Cliff Returns
The federal data shows the ACA marketplace shed roughly 1.2 million enrollees in the 2026 open‑enrollment period, the sharpest drop since the program began. Average monthly premiums climbed 58% to $178, and deductibles rose 37% to $3,786 as consumers shifted to...
Minnesota Charges 15 Providers in $90 Million Medicaid Fraud Scheme Targeting Autism Services
Federal prosecutors have indicted 15 autism and disability service providers in Minnesota for allegedly defrauding Medicaid of roughly $90 million, including a $40 million autism‑program scheme. The charges mark the largest Medicaid fraud cases ever brought in the district and raise questions...
NHSE Publishes Best Practice Guide for Frailty Pathways with Emphasis on Data, Risk Stratification, and Proactive Identification
NHS England released a best‑practice guide to standardise frailty pathways across Integrated Care Boards (ICBs) ahead of the 2026 modern service framework. The guide stresses data‑driven risk stratification, a single frailty dataset, and proactive case finding via neighbourhood‑level plans. It...
Akari Therapeutics Shares Double on KRAS Synergy Data, Raises $5.5M for ADC Trial
Akari Therapeutics' shares surged more than 100% in pre‑market trading after the company disclosed preclinical data that its lead ADC, AKTX-101, works synergistically with KRAS inhibitor Adagrasib in pancreatic cancer models. The biotech also priced a $5.5 million private placement to...
Retatrutide Results Suggest a Change in the Order of Things
Eli Lilly’s phase‑3 trial of retatrutide, a triple‑agonist peptide, showed patients with severe obesity lost an average of 30% of body weight over 80 weeks, a result comparable to bariatric surgery. The study also reported significant improvements in cardiometabolic markers such...
Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?
The FDA is increasingly willing to approve drugs based on a single pivotal trial, a shift described by former FDA Oncology Division Director Harpreet Singh as an evolution rather than a revolution. In oncology, especially for rare, life‑threatening cancers, a...
Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean
MedicNova’s chief business officer David Crean warned that rapid FDA staffing changes and policy shifts are widening variance in drug‑approval timelines, leaving biotech firms scrambling for predictability. Companies are moving regulatory discussions earlier, seeking written confirmations for INDs, type‑B/C protocols,...
Why Health Insurance Needs Transparency W/ Ty Wang, Co-Founder & CEO, Angle Health
In this episode of CareTalk, Ty Wang, co‑founder and CEO of Angle Health, explains why he chose health insurance as the launchpad for his startup, citing the plan’s role as the central data and financing hub of American healthcare. He...
Why ACOs Are Shifting From Claims to Real-Time Network Data
Accountable Care Organizations (ACOs) are moving away from reliance on retrospective claims data toward real‑time clinical network data. Claims arrive weeks after a patient event, keeping ACOs in a reactive mode that hampers timely interventions. By ingesting event notifications—admissions, discharges,...
NICE Changes Stance on Genmab's Cervical Cancer Drug
Two months after rejecting Genmab’s Tivdak, the UK health technology body NICE has reversed course, recommending the antibody‑drug conjugate for adults with recurrent or metastatic cervical cancer. The decision follows a revised economic model that incorporates the innovaTV 301 trial results...
Allergan Aesthetics (AbbVie) Reports CHMP Positive Opinion for Boey to Temporarily Improve Glabellar Lines in Adults
Allergan Aesthetics, a unit of AbbVie, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending Boey (trenibotulinumtoxinE) for the temporary improvement of moderate-to-severe glabellar lines in adults. The recommendation covers all...
Ebola Outbreak Prompts Scrutiny of Trump Cuts
The Trump administration’s deep cuts to USAID’s global health budget and its withdrawal from the World Health Organization are being blamed for a delayed response to the Ebola outbreak in the Democratic Republic of Congo and Uganda. Funding for U.S....
Listen: Can the EU Achieve Pharmaceutical Sovereignty?
European reliance on Asian active pharmaceutical ingredients has left the EU vulnerable, as highlighted by medicine shortages during the COVID‑19 pandemic and the Ukraine war. In response, the European Parliament and Council approved the Critical Medicines Act, which adds EU...
Biogen, Denali Pull Parkinson's Drug After Failed Trial
Biogen has halted development of BIIB122, its LRRK2‑inhibitor partner with Denali, after the phase 2b LUMA trial failed to slow Parkinson’s disease progression despite achieving about 30% target inhibition. The study, which included both LRRK2‑mutated and idiopathic patients, missed its primary...
Transforming the Clinical Stack: Why Deep Intelligence Is the Foundation for Digital Health Integration
The life‑sciences sector is confronting a validation bottleneck as legacy GxP processes slow digital health adoption. Companies are turning to intelligent Electronic Validation Management Systems (EVMS) and Validation Lifecycle Management Systems (VLMS) to automate compliance and cut validation cycles by...
Polpharma Partners with Tuteur to Commercialize a Biosimilar Candidate Across LATAM for Autoimmune Diseases
Polpharma Biologics has signed a licensing deal with Tuteur to bring a biosimilar candidate for autoimmune diseases to Latin America, excluding Brazil. Polpharma will handle development and manufacturing, while Tuteur will manage commercialization, marketing and distribution across the licensed territories....
Liquid Biopsy Differentiation of Pancreatic Cancer From Non‐Cancerous Pancreatic Disease Using Dielectrophoresis‐Recovered Nanoparticles Carrying Cell‐Free DNA and Protein Biomarkers (Small...
Researchers led by Stuart D. Ibsen have unveiled a microfluidic chip that uses dielectrophoretic forces to pull extracellular‑vesicle nanoparticles out of undiluted plasma. The captured vesicles carry cell‑free DNA and protein biomarkers that together distinguish pancreatic cancer from non‑cancerous pancreatic...
Senators Reintroduce Bill to Expand Reimbursement for Radiologist Assistants
Senators John Boozman and Ben Ray Luján reintroduced the Medicare Access to Radiology Care Act (MARCA) to let Medicare reimburse nondiagnostic services performed by radiologist assistants (RAs) in hospitals. The bill seeks to close a reimbursement gap that limits RA...
AdventHealth Cuts Admin Time 80% With ChatGPT
AdventHealth has deployed OpenAI’s ChatGPT across its nine‑state network to automate routine administrative work, achieving an 80 percent reduction in time clinicians spend on utilization management and other back‑office tasks. Physician advisors now reclaim roughly eight minutes per case, while finance,...
FDA Issues Alert for Abiomed Heart Pump Controllers
The FDA issued an early alert for all Abiomed heart‑pump controllers after the company discovered a software flaw that can force the Automated Impella Controller to restart when a patient’s left ventricular Impella device experiences more than 80 minutes of...
At Bio-IT World's 25th Anniversary, Rare Disease Takes Center Stage
At the 25th Bio‑IT World Conference, rare disease took center stage as leaders examined the puzzle from patient, AI‑diagnostic, investment, and policy angles. Patients like Tom Bartlett highlighted the chronic data gap between wearables and clinicians, while AI platforms such...
Return to Sport After Arthroscopic Rotator Cuff Repair: Epidemiology and Prognostic Factors in a Swiss Multi-Centre Cohort
A Swiss multi‑centre cohort of 725 patients undergoing arthroscopic rotator cuff repair (ARCR) tracked return‑to‑sport (RTS) outcomes over two years. By 12 months, 49.5% reported full RTS, rising to 57.4% at 24 months. Multivariable analysis identified younger age, traumatic tear,...
Coroner’s Court, Watchdog to Probe Delayed Blood Transfusion to Girl with Cancer
Hong Kong’s Medical Council and Coroner’s Court will hold a joint inquiry into the death of eight‑year‑old Chau Tin‑yu, who suffered a 48‑minute delayed blood transfusion during a 2020 surgery. The inquiry, set for Oct 27‑30, follows a police malpractice complaint...
Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announced that its Phase II in‑vitro study with the U.S. Army Institute of Surgical Research validated a no‑wash 3 % DMSO cryopreservation protocol, delivering a 94% mean post‑thaw platelet recovery. The protocol also outperformed wash‑based and trehalose approaches on...
BMS Deploys Anthropic’s Claude AI Across Global Drug‑Discovery Operations
Bristol‑Myers Squibb announced a strategic partnership with Anthropic to embed the Claude foundation model into every major function of its global business, covering more than 30,000 employees. The move is billed as a way to break data silos and accelerate...
Intuitive Surgical Rolls Out AI‑assisted Upgrades to Da Vinci 5 Platform
Intuitive Surgical said it will deliver more than 100 software and hardware updates to its da Vinci 5 surgical robot, adding AI‑assisted telepresence, mobile console login and new Force Feedback instruments. The upgrades launch in the United States in June...
Mayo Clinic Teams with Bayesian Health on AI Platform to Cut Palliative Care Readmissions by 25%
Mayo Clinic has partnered with AI specialist Bayesian Health to co‑develop an electronic‑health‑record integrated platform that identified unmet palliative‑care needs early and lowered readmissions by 25% in a randomized trial. The collaboration, run under Mayo’s Practice Transformation Ventures, seeks to...
VA EHR Restart Deemed ‘Phenomenal’ as Rollout Resumes at Michigan Sites
Veterans Affairs Secretary Doug Collins announced that the resumed rollout of the department’s new electronic health record system at four Michigan medical sites was “phenomenal.” The restart follows a multi‑year, $37 billion modernization effort that has been plagued by cost overruns...
HHS OIG Report Finds Vertical Integration Has Minimal Impact on Medicare Drug Prices
The U.S. Health and Human Services Office of Inspector General released a study of 60 high‑use Medicare Part D drugs and found that prices were less than 1% higher for plans that own pharmacy‑benefit managers. The finding questions long‑standing concerns that...
Congressional Push to Revamp Medicare Physician Fees Aims to Halt Hospital Consolidation
U.S. lawmakers are debating reforms to the Medicare physician fee schedule, arguing that stagnant reimbursement is driving independent doctors into hospital systems. The effort, highlighted in a recent House Energy and Commerce subcommittee hearing, seeks to preserve competition and lower...
Digital Suppression of Women’s Health Info Is Affecting Real-World Outcomes – and Government Needs to Act
Big tech platforms are increasingly shadow‑banning legitimate women’s health content, often flagging anatomical terms as adult material. A study commissioned by Essity shows 74% of 18‑34‑year‑olds turn to social media for health advice, yet women’s health posts suffer up to...
TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
TrivarX announced a partnership with specialist CRO Beyond Drug Development to drive the Phase 1 safety trial of its Stabl‑Im oncology imaging platform. Beyond will handle protocol finalisation, regulatory documentation and site selection as TrivarX prepares to dose healthy volunteers in...
Lilly's Retatrutide Shows Early Muscle‑Sparing Weight‑Loss Results
Eli Lilly’s experimental obesity drug retatrutide has produced early trial data indicating up to 33% body‑weight loss with a measurable muscle‑preserving effect. Neuroscientist Andrew Huberman highlighted the drug’s triple‑agonist mechanism and warned against unregulated gray‑market sources.